MIRA PHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
MIRA$0.62+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024
MIRA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash | $2,641,539 | $2,832,931 |
| Prepaid expenses | 61,936 | 54,729 |
| Short-term equity investments, at fair value- related party | 4,894,366 | - |
| Total current assets | 7,597,841 | 2,887,660 |
| Related party accounts receivable | 35,439 | 35,439 |
| Total assets | $7,633,280 | $2,923,099 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable | $83,926 | $423,349 |
| Accrued liabilities | - | 300,000 |
| Total current liabilities | 83,926 | 723,349 |
| Total liabilities | 83,926 | 723,349 |
| Stockholders’ Equity | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized and none issued or outstanding. | - | - |
| Common Stock, $0.0001 par value; 100,000,000 shares authorized, 39,511,492 and 16,560,852 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively. | 3,951 | 1,656 |
| Additional paid-in capital | 41,142,288 | 31,335,815 |
| Accumulated deficit | (33,596,885) | (29,137,721) |
| Total stockholders’ equity | 7,549,354 | 2,199,750 |
| Total liabilities and stockholders’ equity | $7,633,280 | $2,923,099 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended September 30, | Nine Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: · $ · - · $ · - · $ · - · $ · - | ||||
| Operating costs: | ||||
| General and administrative expenses | 904,346 | 1,014,223 | 3,445,045 | 3,136,393 |
| Research and development expenses | 412,639 | 1,067,396 | 1,223,240 | 2,444,134 |
| Total operating costs | 1,316,985 | 2,081,619 | 4,668,285 | 5,580,527 |
| Interest income | 15,697 | 37,752 | 45,741 | 127,564 |
| Unrealized gain on short-term investments | 176,056 | - | 176,056 | - |
| Other expense | (12,441) | - | (12,676) | - |
| Other income, expense, net | 179,312 | 37,752 | 209,121 | 127,564 |
| Net loss | (1,137,673) | (2,043,867) | (4,459,164) | (5,452,963) |
| Deemed dividend | (21,556,821) | - | (21,556,821) | - |
| Net loss attributable to common shareholders | $(22,694,494) | $(2,043,867) | $(26,015,985) | $(5,452,963) |
| Basic and diluted loss per share | $(1.18) | $(0.14) | $(1.45) | $(0.36) |
| Weighted average common stock shares outstanding, basic and diluted | 19,274,947 | 15,071,915 | 17,984,641 | 15,071,915 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, December 31, 2023 | 14,780,885 | $1,478 | $25,657,930 | $(21,285,062) | $4,374,346 |
| Stock-based compensation | - | - | 500,210 | - | 500,210 |
| Net loss | - | - | - | (1,717,771) | (1,717,771) |
| Balances, March 31, 2024 | 14,780,885 | 1,478 | 26,158,140 | (23,002,833) | 3,156,785 |
| Payment of Short Swing Disgorgement by Bay Shore Trust | - | - | 148,703 | - | 148,703 |
| Stock-based compensation | - | - | 604,803 | - | 604,803 |
| Net loss | - | - | - | (1,691,325) | (1,691,325) |
| Balances, June 30, 2024 | 14,780,885 | 1,478 | 26,911,646 | (24,694,158) | 2,218,966 |
| Issuance of common stock under ATM | 1,485,263 | 149 | 3,129,476 | - | 3,129,625 |
| Stock-based compensation | - | - | 269,014 | - | 269,014 |
| Net loss | - | - | - | (2,043,867) | (2,043,867) |
| Balances, September 30, 2024 | 16,266,148 | $1,626 | $30,310,136 | $(26,738,025) | $3,573,737 |
| Balances, December 31, 2024 | 16,560,852 | $1,656 | $31,335,815 | $(29,137,721) | $2,199,750 |
| Issuance of common stock under ATM, net of costs | 2,802 | 1 | 3,381 | - | 3,382 |
| Shares issued for vested RSUs | 250,000 | 25 | (25) | - | - |
| Stock-based compensation | - | - | 874,812 | - | 874,812 |
| Net loss | - | - | - | (1,783,779) | (1,783,779) |
| Balances, March 31, 2025 | 16,813,654 | 1,682 | 32,213,983 | (30,921,500) | 1,294,165 |
| Issuance of common stock under ATM, net of costs | 321,486 | 31 | 323,808 | - | 323,839 |
| Shares issued for vested RSUs | 250,000 | 25 | (25) | - | - |
| Stock-based compensation | - | - | 489,566 | - | 489,566 |
| Net loss | - | - | - | (1,537,712) | (1,537,712) |
| Balances, June 30, 2025 | 17,385,140 | 1,739 | 33,027,332 | (32,459,212) | 569,859 |
| Issuance of common stock, ATM, net of costs | 2,058,114 | 206 | 2,710,020 | - | 2,710,226 |
| Issuance of common stock, SKNY acquisition | 19,755,738 | 1,976 | 4,716,335 | - | 4,718,311 |
| Shares issued for vested RSU | 62,500 | 6 | 93,744 | - | 93,750 |
| Stock option exercises | 250,000 | 25 | 297,767 | - | 297,792 |
| Stock-based compensation | - | - | 297,090 | - | 297,090 |
| Net loss | - | - | - | (1,137,673) | (1,137,673) |
| Balances, September 30, 2025 | 39,511,492 | $3,951 | $41,142,288 | $(31,321,539) | $7,549,354 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.